Assem Farhat, MD
Interventional Cardiology · Wichita, KSNPI 1720070907
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $6,772 of the $9,363 with a category attached, or 72.3%. Medtronic accounts for 62.1% of it on its own, with 24 other manufacturers making up the rest. 2025 is the largest year on record at $3,835, 3.6 times the $1,068 reported in 2019. That places this record below the midpoint for interventional cardiology clinicians in KS, where the typical reported total is $8,846.
Across 200 payments — averaging $46.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$6K
- Abbott$659
- Abiomed$529
- Shockwave Medical, Inc$329
- Novartis$326
- AstraZeneca$306
- plus $1K from 19 others
What the payments were for
- Travel & lodging$2,45726%
- Food & beverage$6,77272%
- Education$1331%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 69 | $5,812 |
| Abbott | 7 | $659 |
| Abiomed | 5 | $529 |
| Shockwave Medical, Inc | 4 | $329 |
| Novartis | 21 | $326 |
| AstraZeneca | 11 | $306 |
| Cvrx, Inc. | 3 | $175 |
| Amgen | 10 | $175 |
| Johnson & Johnson | 15 | $166 |
| Pfizer | 9 | $153 |
| E.r. Squibb & Sons, L.L.C. | 10 | $144 |
| Sanofi-aventis U.S. LLC | 11 | $128 |
| Boehringer Ingelheim | 5 | $84 |
| Astellas Pharma US Inc | 1 | $77 |
| Actelion Pharmaceuticals US, Inc. | 3 | $73 |
| Regeneron Healthcare Solutions, Inc. | 3 | $54 |
| Amarin Pharma, Inc. | 2 | $33 |
| Boston Scientific | 2 | $30 |
| Merck | 1 | $22 |
| Bardy Diagnostics, Inc. | 3 | $16 |
| Bayer | 1 | $16 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $15 |
| Scpharmaceuticals Inc. | 1 | $14 |
| Kowa Pharmaceuticals America, Inc. | 1 | $13 |
| Surmodics, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Micra$514
- Impella$501
- WAINUA$161
- ASSURITY$156
- Barostim Neo System$141
- AVEIR$140
- LINQ II$126
- OPTIS$121
- Vascular Lithotripsy$112
- MitraClip$110
How this compares
$9,363 in reported general payments places this provider in the 50th percentile of 55 interventional cardiology providers in Kansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 834 | $813,087 |
| EntrestoSacubitril/Valsartan | 238 | $247,754 |
| XareltoRivaroxaban | 154 | $184,344 |
| Repatha SureclickEvolocumab | 157 | $115,738 |
| FarxigaDapagliflozin Propanediol | 47 | $54,815 |
| Praluent PenAlirocumab | 37 | $28,318 |
| BrilintaTicagrelor | 37 | $24,795 |
| Flecainide Acetate | 195 | $8,466 |
| Metoprolol Succinate | 711 | $6,815 |
| MultaqDronedarone Hcl | 11 | $6,324 |
| Dabigatran EtexilateDabigatran Etexilate Mesylate | 11 | $5,603 |
| SotalolSotalol Hcl | 337 | $5,335 |
| Amiodarone Hcl | 265 | $4,880 |
| Diltiazem 12hr ErDiltiazem Hcl | 15 | $3,926 |
| ClopidogrelClopidogrel Bisulfate | 490 | $3,704 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $153 | $813,087834 claims |
| NovartisEntresto | $326 | $247,754238 claims |
| Johnson & JohnsonXarelto | $166 | $184,344154 claims |
| AstraZenecaFarxiga, Brilinta | $306 | $79,61084 claims |
| Sanofi-aventis U.S. LLCMultaq | $128 | $6,32411 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 55 interventional cardiology providers in Kansas.
Other interventional cardiology in Wichita
- Maheedhar GedelaWichita$54K
- Hussam FarhoudWichita$25K
- Christian HouraniWichita$17K
- Gaurav TyagiWichita$13K
- Ravi BajajWichita$10K
- Venkata BoppanaWichita$9K
- Alaa BouladWichita$8K
- Rohma ShaikhWichita$4K
- George ReaderWichita$4K
- Mohamed ElmassryWichita$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.